Theriva Biologics, Inc.

Theriva Biologics (TOVX) shows no cyber incidents or major red-flag 8-K filings in our 90-day monitoring window, though low signal in this timeframe does not imply low overall risk. The full $49 Report extends analysis to 12 months of SEC filings, applies our dilution risk scoring model, and contextualizes the company's financing history and capital structure against peer benchmarks. We also layer in AI-driven signals for potential governance and operational stress factors not visible in headline filings. The full $49 Report adds quantified dilution risk, complete 8-K context with officer and financing activity, and forward-looking risk signals derived from filing language and financial trends.